Neurosense Therapeutics Ltd- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Neurosense Therapeutics Ltd 公司

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Neurosense Therapeutics Ltd简介



公司代码NRSN

公司名称Neurosense Therapeutics Ltd

上市日期Dec 09, 2021

CEOBen-Noon (Alon)

员工数量15

证券类型Ordinary Share

年结日Dec 09

公司地址11 Hamenofim St.

城市HERZLIYA

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Israel

邮编4672562

电话97297996183

网址https://www.neurosense-tx.com/

公司代码NRSN

上市日期Dec 09, 2021

CEOBen-Noon (Alon)

Neurosense Therapeutics Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Alon Ben-Noon

Chief Executive Officer, Director

3.18M

+93666.00%

Mr. Or Eisenberg

Chief Financial Officer

480.92K

+20916.00%

Dr. Ferenc Tracik

Chief Medical Officer

189.62K

+66667.00%

Mr. Mark W. Leuchtenberger

Independent Non-Executive Chairman of the Board

64.00K

--

Mr. Cary J. Claiborne

Non-Executive Independent Director

24.00K

--

Ms. Christine A. Pellizzari, J.D.

Non-Executive Independent Director

--

Ms. Caren Deardorf

Non-Executive Independent Director

--

Dr. Revital Mandil-Levin, Ph.D.

Non-Executive Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Alon Ben-Noon

Chief Executive Officer, Director

3.18M

+93666.00%

Mr. Or Eisenberg

Chief Financial Officer

480.92K

+20916.00%

Dr. Ferenc Tracik

Chief Medical Officer

189.62K

+66667.00%

Mr. Mark W. Leuchtenberger

Independent Non-Executive Chairman of the Board

64.00K

--

Mr. Cary J. Claiborne

Non-Executive Independent Director

24.00K

--

Ms. Christine A. Pellizzari, J.D.

Non-Executive Independent Director

--

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 1月31日周六

持股股东

股东类型

持股股东

占比

Ben-Noon (Alon)

10.69%

Rimon Gold Assets Ltd

7.76%

Eisenberg (Or)

1.62%

Tracik (Ferenc)

0.64%

Squarepoint Capital LLP

0.32%

其他

78.97%

持股股东

占比

Ben-Noon (Alon)

10.69%

Rimon Gold Assets Ltd

7.76%

Eisenberg (Or)

1.62%

Tracik (Ferenc)

0.64%

Squarepoint Capital LLP

0.32%

其他

78.97%

股东类型

持股股东

占比

Individual Investor

13.78%

Corporation

7.76%

Investment Advisor/Hedge Fund

0.37%

Investment Advisor

0.35%

Research Firm

0.15%

Hedge Fund

0.07%

Bank and Trust

0.05%

其他

77.47%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

30

293.14K

0.99%

-2.10M

2025Q3

29

437.13K

1.75%

-1.60M

2025Q2

37

7.64M

31.03%

+143.76K

2025Q1

39

7.45M

37.28%

+353.50K

2024Q4

38

7.90M

34.02%

+1.29M

2024Q3

32

5.18M

22.45%

-1.31M

2024Q2

35

6.62M

30.57%

+1.57M

2024Q1

38

5.18M

33.20%

-953.28K

2023Q4

38

5.12M

32.81%

-1.05M

2023Q3

33

5.76M

47.99%

-945.27K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Ben-Noon (Alon)

3.18M

10.69%

+93.67K

+3.04%

Apr 07, 2025

Rimon Gold Assets Ltd

2.30M

7.76%

+2.30M

--

Dec 02, 2024

Eisenberg (Or)

480.92K

1.62%

+20.92K

+4.55%

Apr 07, 2025

Tracik (Ferenc)

189.62K

0.64%

+66.67K

+54.22%

Apr 07, 2025

Squarepoint Capital LLP

95.38K

0.32%

+45.45K

+91.04%

Sep 30, 2025

Russek-Blum (Niva)

75.43K

0.25%

+10.00K

+15.28%

Apr 07, 2025

Leuchtenberger (Mark W)

64.00K

0.22%

--

Apr 07, 2025

Morgan Stanley & Co. LLC

41.40K

0.14%

-38.50K

-48.19%

Sep 30, 2025

Meitav Investment House Ltd

40.00K

0.13%

--

Sep 30, 2025

Binder (Hagit)

32.00K

0.11%

+10.00K

+45.45%

Apr 07, 2025

持股ETF



机构名称

占比

暂无数据

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据